Related Experiment Video
Updated: Dec 26, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification
Mengmeng Jie1, Yaran Wu1, Mengyuan Gao1
1Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Background:
Aberrant expression of circular RNAs contributes to the initiation and progression of cancers, but the underlying mechanism remains elusive.
Methods:
RNA-seq and qRT-PCR were performed to screen differential expressed circRNAs between gastric cancer tissues and adjacent normal tissues. Candidate circRNA (circMRPS35) was screened out and validated by qRT-PCR. Cell proliferation and invasion ability were determined by CCK-8 and cell invasion assays. RNA-seq, GO-pathway, RNA pull-down and ChIRP were further applied to search for detailed mechanism.
Results:
Here, a novel circRNA named circMRPS35, was screened out by RNA-seq in gastric cancer tissues, whose expression is related to clinicopathological characteristics and prognosis in gastric cancer patients. Biologically, circMRPS35 suppresses the proliferation and invasion of gastric cancer cells in vitro and in vivo. Mechanistically, circMRPS35 acts as a modular scaffold to recruit histone acetyltransferase KAT7 to the promoters of FOXO1 and FOXO3a genes, which elicits acetylation of H4K5 in their promoters. Particularly, circMRPS35 specifically binds to FOXO1/3a promoter regions directly. Thus, it dramatically activates the transcription of FOXO1/3a and triggers subsequent response of their downstream target genes expression, including p21, p27, Twist1 and E-cadherin, resulting in the inhibition of cell proliferation and invasion. Moreover, circMRPS35 expression positively correlates with that of FOXO1/3a in gastric cancer tissues.
Conclusions:
Our findings not only reveal the pivotal roles of circMRPS35 in governing histone modification in anticancer treatment, but also advocate for triggering circMRPS35/KAT7/FOXO1/3a pathway to combat gastric cancer.
Insights
Circular RNA circMRPS35 suppresses gastric cancer progression by recruiting KAT7 to activate FOXO1/3a transcription. This novel circMRPS35/KAT7/FOXO1/3a pathway offers a potential therapeutic target for gastric cancer.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Aberrant circular RNA (circRNA) expression is implicated in cancer development.
- The precise mechanisms by which circRNAs influence cancer progression remain largely unknown.
Purpose of the Study:
- To identify and characterize novel circRNAs involved in gastric cancer.
- To elucidate the molecular mechanisms underlying the function of a specific circRNA in gastric cancer.
Main Methods:
- RNA sequencing (RNA-seq) and quantitative real-time PCR (qRT-PCR) for circRNA screening.
- Cell proliferation (CCK-8) and invasion assays to assess cellular functions.
- RNA pull-down and Chromatin Isolation by RNA Purification (ChIRP) to investigate molecular interactions and mechanisms.
Main Results:
- A novel circRNA, circMRPS35, was identified and validated in gastric cancer tissues, correlating with clinicopathological features and prognosis.
- circMRPS35 demonstrated suppression of gastric cancer cell proliferation and invasion in vitro and in vivo.
- Mechanistically, circMRPS35 recruits histone acetyltransferase KAT7 to the promoters of FOXO1 and FOXO3a, enhancing their transcription via H4K5 acetylation and activating downstream tumor-suppressive genes.
Conclusions:
- circMRPS35 plays a critical role in regulating histone modification and inhibiting gastric cancer.
- The circMRPS35/KAT7/FOXO1/3a axis represents a promising therapeutic target for gastric cancer treatment.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

